细化稳定期COPD管理流程和随访策略：2020版GOLD指南解读

doi:10.16150/j.1671-2870.2020.04.006

摘要/Abstract

中图分类号:

R563.3

李庆云, 孙娴雯. 细化稳定期COPD管理流程和随访策略：2020版GOLD指南解读[J]. 诊断学理论与实践, 2020, 19(04): 354-358.

图/表 1

参考文献 40

[1]	Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (updated 2020)[R/OL]. http://goldcopd.org/.
[2]	Çolak Y, Nordestgaard BG, Vestbo J, et al. Prognostic significance of chronic respiratory symptoms in indivi-duals with normal spirometry[J]. Eur Respir J, 2019, 54(3):1900734. doi: 10.1183/13993003.00734-2019 URL
[3]	Haroon S, Adab P, Riley RD, et al. Predicting risk of undiagnosed COPD: development and validation of the Target COPD score[J]. Eur Respir J, 2017, 49(6):1602191. doi: 10.1183/13993003.02191-2016 URL
[4]	Huang WC, Wu MF, Chen HC, et al. Features of COPD patients by comparing CAT with mMRC: a retrospective, cross-sectional study[J]. NPJ Prim Care Respir Med, 2015, 25:15063. doi: 10.1038/npjpcrm.2015.63 URL
[5]	Cheng SL, Lin CH, Wang CC, et al. Comparison between COPD assessment test (CAT) and modified Medical Research Council (mMRC) dyspnea scores for evaluation of clinical symptoms, comorbidities and medical resources utilization in COPD patients[J]. J Formos Med Assoc, 2019, 118(1 Pt 3):429-435. doi: 10.1016/j.jfma.2018.06.018 URL
[6]	Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort[J]. Lancet Respir Med, 2017, 5(8):619-626. doi: 10.1016/S2213-2600(17)30207-2 URL
[7]	Benson VS, Pascoe KC, Siddall J, et al. Exacerbation frequency and eosinophil counts among patients with COPD currently prescribed triple therapy[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:2711-2723. doi: 10.2147/COPD.S217503 URL
[8]	Le Rouzic O, Roche N, Cortot AB, et al. Defining the "frequent exacerbator" phenotype in COPD: a hypothesis-free approach[J]. Chest, 2018, 153(5):1106-1115. doi: 10.1016/j.chest.2017.10.009 URL
[9]	Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α(1)-antitrypsin deficiency[J]. Eur Respir J, 2017, 50(5):1700610. doi: 10.1183/13993003.00610-2017 URL
[10]	Stockley RA, Edgar RG, Pillai A, et al. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?[J]. Int J Chron Obstruct Pulmon Dis, 2016, 11:1745-1756. doi: 10.2147/COPD.S111508 URL
[11]	Takei N, Suzuki M, Makita H, et al. Serum alpha-1 antitrypsin levels and the clinical course of chronic obstructive pulmonary disease[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:2885-2893. doi: 10.2147/COPD.S225365 URL
[12]	Balbi B, Sangiorgi C, Gnemmi I, et al. Bacterial load and inflammatory response in sputum of alpha-1 antitrypsin deficiency patients with COPD[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:1879-1893. doi: 10.2147/COPD.S207203 URL
[13]	McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial(RAPID-OLE)[J]. Lancet Respir Med, 2017, 5(1):51-60. doi: 10.1016/S2213-2600(16)30430-1 pmid: 27916480
[14]	Effing TW, Vercoulen JH, Bourbeau J, et al. Definition of a COPD self-management intervention: International Expert Group consensus[J]. Eur Respir J, 2016, 48(1):46-54. doi: 10.1183/13993003.00025-2016 pmid: 27076595
[15]	Kessler R, Casan-Clara P, Koehler D, et al. COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD[J]. Eur Respir J, 2018, 51(1):1701612. doi: 10.1183/13993003.01612-2017 URL
[16]	Rose L, Istanboulian L, Carriere L, et al. Program of integrated care for patients with chronic obstructive pulmonary disease and multiple comorbidities (PIC COPD(+): a randomised controlled trial[J]. Eur Respir J, 2018, 51(1):1701567. doi: 10.1183/13993003.01567-2017 URL
[17]	Benzo R, McEvoy C. Effect of health coaching delivered by a respiratory therapist or nurse on self-management abilities in severe COPD: analysis of a large randomized study[J]. Respir Care, 2019, 64(9):1065-1072. doi: 10.4187/respcare.05927 URL
[18]	Cho-Reyes S, Celli BR, Dembek C, et al. Inhalation technique errors with metered-dose inhalers among patients with obstructive lung diseases: a systematic review and meta-analysis of U.S. studies[J]. Chronic Obstr Pulm Dis, 2019, 6(3):267-280. doi: 10.15326/jcopdf.6.3.2018.0168 pmid: 31342732
[19]	Sulaiman I, Cushen B, Greene G, et al. Objective assessment of adherence to inhalers by patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med, 2017, 195(10):1333-1343. doi: 10.1164/rccm.201604-0733OC URL
[20]	Alison JA, McKeough ZJ, Johnston K, et al. Australian and New Zealand Pulmonary Rehabilitation Guidelines[J]. Respirology, 2017, 22(4):800-819. doi: 10.1111/resp.13025 URL
[21]	Horton EJ, Mitchell KE, Johnson-Warrington V, et al. Comparison of a structured home-based rehabilitation programme with conventional supervised pulmonary rehabilitation: a randomised non-inferiority trial[J]. Thorax, 2018, 73(1):29-36. doi: 10.1136/thoraxjnl-2016-208506 URL
[22]	Nolan CM, Kaliaraju D, Jones SE, et al. Home versus outpatient pulmonary rehabilitation in COPD: a propensity-matched cohort study[J]. Thorax, 2019, 74(10):996-998. doi: 10.1136/thoraxjnl-2018-212765 URL
[23]	Wootton SL, Hill K, Alison JA, et al. Effects of ongoing feedback during a 12-month maintenance walking program on daily physical activity in people with COPD[J]. Lung, 2019, 197(3):315-319. doi: 10.1007/s00408-019-00216-5 pmid: 30982940
[24]	Coultas DB, Jackson BE, Russo R, et al. Home-based physical activity coaching, physical activity, and health care utilization in chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease self-management activation research trial secondary outcomes[J]. Ann Am Thorac Soc, 2018, 15(4):470-478. doi: 10.1513/AnnalsATS.201704-308OC pmid: 29283670
[25]	Gordon CS, Waller JW, Cook RM, et al. Effect of pulmonary rehabilitation on symptoms of anxiety and depression in COPD: a systematic review and meta-analysis[J]. Chest, 2019, 156(1):80-91. doi: S0012-3692(19)30873-6 pmid: 31034818
[26]	Alison JA, McKeough ZJ, Leung RWM, et al. Oxygen compared to air during exercise training in COPD with exercise-induced desaturation[J]. Eur Respir J, 2019, 53(5):1802429. doi: 10.1183/13993003.02429-2018 URL
[27]	Kopsaftis Z, Wood-Baker R, Poole P. Influenza vaccine for chronic obstructive pulmonary disease (COPD)[J]. Cochrane Database Syst Rev, 2018, 6(6):CD002733.
[28]	Gershon AS, Chung H, Porter J, et al. Influenza vaccine effectiveness in preventing hospitalizations in older patients with chronic obstructive pulmonary disease[J]. J Infect Dis, 2020, 221(1):42-52. doi: 10.1093/infdis/jiz419 pmid: 31549165
[29]	Figueira Gonçalves JM, García Bello MA, Bethencourt Martín N, et al. Impact of 13-valent pneumococcal conjugate polysaccharide vaccination on severe exacerbations in patients with chronic obstructive pulmonary di-sease and established cardiovascular disease[J]. Eur J Intern Med, 2019, 63:e14-e16.
[30]	Szmidt MK, Kaluza J, Harris HR, et al. Long-term dietary fiber intake and risk of chronic obstructive pulmonary disease: a prospective cohort study of women[J/OL]. Eur J Nutr, 2019-06-06[2020-02-21]. https://pubmed.ncbi.nlm.nih.gov/31280344/.
[31]	Gouzi F, Maury J, Héraud N, et al. Additional effects of nutritional antioxidant supplementation on peripheral muscle during pulmonary rehabilitation in COPD patients: a randomized controlled trial[J]. Oxid Med Cell Longev, 2019, 2019:5496346.
[32]	Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-analysis of individual participant data from randomised controlled trials[J]. Thorax, 2019, 74(4):337-345. doi: 10.1136/thoraxjnl-2018-212092 pmid: 30630893
[33]	Costi S, Crisafulli E, Trianni L, et al. Baseline exercise tolerance and perceived dyspnea to identify the ideal candidate to pulmonary rehabilitation: a risk chart in COPD patients[J]. Int J Chron Obstruct Pulmon Dis, 2019, 14:3017-3023. doi: 10.2147/COPD.S223038 URL
[34]	Tavares-Silva E, Donatto FF, Medeiros RMV, et al. Carbohydrate supplementation and psychophysiological responses during moderate exercise in hypoxia[J]. J Int Soc Sports Nutr, 2020, 17(1):3. doi: 10.1186/s12970-019-0331-6 URL
[35]	Beaumont M, Forget P, Couturaud F, et al. Effects of inspiratory muscle training in COPD patients: a systematic review and meta-analysis[J]. Clin Respir J, 2018, 12(7):2178-2188. doi: 10.1111/crj.12905 pmid: 29665262
[36]	Beaumont M, Mialon P, Le Ber C, et al. Effects of inspiratory muscle training on dyspnoea in severe COPD patients during pulmonary rehabilitation: controlled randomised trial[J]. Eur Respir J, 2018, 51(1):1701107. doi: 10.1183/13993003.01107-2017 URL
[37]	Charususin N, Gosselink R, Decramer M, et al. Randomised controlled trial of adjunctive inspiratory muscle training for patients with COPD[J]. Thorax, 2018, 73(10):942-950. doi: 10.1136/thoraxjnl-2017-211417 pmid: 29914940
[38]	Velloso M, Jardim JR. Study of energy expenditure du-ring activities of daily living using and not using body position recommended by energy conservation techniques in patients with COPD[J]. Chest, 2006, 130(1):126-132. doi: 10.1378/chest.130.1.126 URL
[39]	Lenferink A, Brusse-Keizer M, van der Valk PD, et al. Self-management interventions including action plans for exacerbations versus usual care in patients with chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2017, 8(8):CD011682.
[40]	Howcroft M, Walters EH, Wood-Baker R, et al. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2016, 12(12):CD005074.

细化稳定期COPD管理流程和随访策略：2020版GOLD指南解读

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 40

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孙娴雯, 李庆云. 新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读[J]. 诊断学理论与实践, 2022, 21(01): 32-37.
[2]	李庆云, 孙娴雯. 慢性阻塞性肺疾病稳定期管理的几个新视点：2021版 GOLD指南解读[J]. 诊断学理论与实践, 2021, 20(01): 43-47.
[3]	陈宇清, 王铭杰, 朱东, 吕城坚, 陈萍. 稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者的气道阻力对呼出气流受限的影响分析[J]. 诊断学理论与实践, 2019, 18(04): 418-422.
[4]	周敏, 张秋蕊. 呼吸道、肠道微生物菌群对慢性阻塞性肺疾病的发病及治疗的影响[J]. 诊断学理论与实践, 2019, 18(03): 246-249.
[5]	李媛媛, 张舒, 曹波, 陆晓晔, 刘黎, 陈杰, 归茜, 徐欣晖, 吕利雄, 朱长清,. 几种感染性疾病中外周血T淋巴细胞亚群变化的检测及其临床意义研究[J]. 诊断学理论与实践, 2015, 14(04): 363-366.
[6]	李庆云, 过依,. 慢性阻塞性肺疾病急性加重评估及稳定期用药选择:慢性阻塞性肺疾病全球倡议2015解读[J]. 诊断学理论与实践, 2015, 14(03): 215-218.
[7]	陈宇清, 吕成坚, 周新, 朱东,. 合并限制性通气功能障碍对稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者运动能力的影响[J]. 诊断学理论与实践, 2012, 11(04): 387-390.
[8]	邓伟吾,. 丙型肝炎病毒感染与慢性呼吸道疾病关系的认识[J]. 诊断学理论与实践, 2011, 10(05): 397-400.
[9]	马冠华, 杨昆, 李敏, 叶亮, 万欢英,. 呼吸道合胞病毒感染对慢性阻塞性肺疾病急性加重期患者的影响[J]. 诊断学理论与实践, 2010, 9(05): 503-506.
[10]	梁丽, 马佳韵, 李庆云, 陈振和, 周敏,. 慢性阻塞性肺疾病合并阻塞性睡眠呼吸暂停低通气综合征的临床特征[J]. 诊断学理论与实践, 2009, 8(06): 612-615.
[11]	陈宇清, 周新, 朱东, 戴晓敏,. 稳定期Ⅱ、Ⅲ级慢性阻塞性肺疾病患者的吸气分数与呼吸肌力研究[J]. 诊断学理论与实践, 2007, 6(05): 409-411.
[12]	郝筱倩, 董蕾, 赵菊辉, 王玉环, 罗金燕,. 2型糖尿病患者小肠移行性复合运动规律的研究[J]. 诊断学理论与实践, 2006, 5(04): 323-326.
[13]	余健民,. 趋化因子和细胞黏附分子在呼吸系统疾病诊断中的应用[J]. 诊断学理论与实践, 2006, 5(02): 109-112.
[14]	秦慧, 李燕芹, 刘斌, 赵旭霁, 查琼芳, 邹静, 陈燕,. 呼气负压技术检测呼气流速受限在慢性阻塞性肺疾病中的应用[J]. 诊断学理论与实践, 2006, 5(02): 116-119.
[15]	谢灿茂, 周宇麒,. 慢性阻塞性肺疾病急性加重的现代评价[J]. 诊断学理论与实践, 2006, 5(02): 106-108.